AeroRx Therapeutics raises $21 million in Series A financing led by Avalon BioVentures to advance AERO-007 for COPD.

Oct 07, 2025•3 days ago

Amount Raised

$21 Million

Round Type

series a

La JollaBiotechnologyHealth Care

Investors

Alexandria Venture InvestmentsCorrelation VenturesAvalon Bio Ventures

Description

AeroRx Therapeutics announced a $21 million Series A financing led by Avalon BioVentures, with participation from Correlation Ventures and Alexandria Venture Investments. The funds will support late-stage clinical development of AERO-007, a potential first-line treatment for COPD. Data from a Phase 2a study showed AERO-007 was well tolerated and provided sustained bronchodilation. This financing positions AeroRx to advance toward a Phase 2b dose-optimization study.

Company Information

Company

AeroRx Therapeutics

Location

La Jolla, California, United States

About

AeroRx Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing proprietary nebulized combination therapies for chronic respiratory diseases. Their lead candidate, inhaled AERO-007, is a novel nebulized LABA/LAMA treatment for chronic obstructive pulmonary disease (COPD). The company aims to improve patient adherence and outcomes by providing an alternative to traditional inhalers.

Related People

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends